New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...
Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer's drug—are poised ...
Patients enrolled on the Children's Oncology Group neuroblastoma biology study ANBL00B1 (ClinicalTrials.gov identifier: NCT00904241) who received care at the University of Chicago (UChicago) or the ...
Managing non-EDC (Electronic Data Capture) data integration in clinical trials is a challenge that holds significant promise. As clinical studies continue to draw on data from wearable devices like ...
Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...
It’s widely known that artificial intelligence (AI) is profoundly reshaping the healthcare industry. Hospitals have used AI in a variety of ways, from streamlining workflows to aiding in bedside ...
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback